IP Library Granted Patent US 10,507,183
Granted Patent B2
US 10,507,183 · App. 15/887,693 · Granted Dec 17, 2019

Cleavable lipids

Inventors: Braydon Charles Guild (Concord, MA); Michael Heartlein (Boxborough, MA); Frank DeRosa (Chelmsford, MA); Jerry Chi Zhang (Lexington, MA)
Assignee: Translate Bio, Inc.
A61K9/19A61K9/1271A61K9/1272A61K31/7088A61K38/45A61K38/465A61K38/47A61K38/50C07C323/25C07C323/27C07C323/44C07D233/64C07J41/0055C07J43/003C12N15/88A61K9/5123C12Y201/03003C12Y203/01C12Y207/08015C12Y301/06C12Y302/01022C12Y302/01035C12Y302/01046C12Y302/01076C12Y305/03001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,183
App. No.
15/887,693
Granted
Dec 17, 2019
Kind
B2
Abstract

Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Claims (9)

1. A lyophilized pharmaceutical composition comprising a lipid nanoparticle and a lyoprotectant that is trehalose,

wherein the lipid nanoparticle comprises

ornithine transcarbamylase mRNA,

a cationic lipid,

a PEG-modified lipid that is DMG-PEG2000,

a non-cationic lipid that is 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), and

a helper lipid that is cholesterol.

2. The lyophilized pharmaceutical composition of claim 1 , wherein the composition is in a form selected from intravenous, oral, rectal, vaginal, transmucosal, sublingual, subdural, nasal, intramuscular, subcutaneous, intramedullar injection, intrathecal, intraventricular, intraperitoneal, intranasal, ophthalmic, and intraocular.

3. The lyophilized pharmaceutical composition of claim 1 , wherein the composition has an encapsulation efficiency greater than about 80%.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: GUILD, BRAYDON CHARLES; HEARTLEIN, MICHAEL; DEROSA, FRANK; ZHANG, JERRY CHI
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 044857/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 045278/0492 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 045285/0231 →
Continuity (5)
Continuation 15651832 · Jul 17, 2017
Continuation 14124615
Provisional Application 61494745 · Jun 8, 2011
Provisional Application 61494882 · Jun 8, 2011
Related Publication 20180169020A1 · Jun 21, 2018
Cited By (4)
US 12,458,604 US 12,559,450 US 12,576,040 US 12,605,464